Why the study?
Many hERG-blocking drugs can cause long QT syndrome and life-threatening arrhythmias, but the molecular mechanisms determining this risk remain unclear.
Population
hERG voltage-gated K+ channels
Comparison
Nifekalant block and facilitation effects
Design
Kinetic and atomistic modeling with voltage-clamp measurements
Key result
Nifekalant facilitates hERG K+ channel current through an agonism-while-blocking mechanism, which may contribute to the relative safety of certain hERG blockers.
Authors
Loading...
May refine arrhythmia risk models for hERG blockers; leaves open clinical relevance of facilitation.
An agonism-while-blocking mechanism explains how certain hERG blockers like nifekalant induce current facilitation, which may counteract their arrhythmogenic potential.
Docken et al. (2026) studied Long QT syndrome and cardiac arrhythmias. Nifekalant (hERG blockers) was evaluated on hERG current facilitation and channel gating mechanisms. Nifekalant facilitates hERG K+ channel current through an agonism-while-blocking mechanism, which may contribute to the relative safety of certain hERG blockers.